| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A195940 from our risk checks.
HK inno.N Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩37,700.00 |
| 52 Week High | ₩47,450.00 |
| 52 Week Low | ₩27,900.00 |
| Beta | 0 |
| 11 Month Change | -1.05% |
| 3 Month Change | 1.75% |
| 1 Year Change | 27.80% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| A195940 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 1.5% | 1.3% | -0.01% |
| 1Y | 27.8% | 9.0% | 5.0% |
Return vs Industry: A195940 exceeded the KR Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: A195940 exceeded the KR Market which returned 5% over the past year.
Price Volatility
| A195940 volatility | |
|---|---|
| A195940 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A195940 has not had significant price volatility in the past 3 months.
Volatility Over Time: A195940's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,695 | Dal-Won Kwak | www.inno-n.com |
HK inno N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition.
HK inno.N Corporation Fundamentals Summary
| A195940 fundamental statistics | |
|---|---|
| Market cap | ₩1.07t |
| Earnings (TTM) | ₩41.49b |
| Revenue (TTM) | ₩839.63b |
0.0x
P/E Ratio0.0x
P/S RatioIs A195940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A195940 income statement (TTM) | |
|---|---|
| Revenue | ₩839.63b |
| Cost of Revenue | ₩491.45b |
| Gross Profit | ₩348.18b |
| Other Expenses | ₩306.69b |
| Earnings | ₩41.49b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A195940 perform over the long term?
See historical performance and comparison